167 related articles for article (PubMed ID: 24218408)
1. A longitudinal analysis of the effect of mass drug administration on acute inflammatory episodes and disease progression in lymphedema patients in Leogane, Haiti.
Eddy BA; Blackstock AJ; Williamson JM; Addiss DG; Streit TG; Beau de Rochars VM; Fox LM
Am J Trop Med Hyg; 2014 Jan; 90(1):80-8. PubMed ID: 24218408
[TBL] [Abstract][Full Text] [Related]
2. Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Fischer PU; King CL; Jacobson JA; Weil GJ
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005163. PubMed ID: 28056015
[No Abstract] [Full Text] [Related]
3. Albendazole for mass drug administration to eliminate lymphatic filariasis.
Sabesan S
Lancet Infect Dis; 2006 Nov; 6(11):684-5. PubMed ID: 17067916
[No Abstract] [Full Text] [Related]
4. Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti.
de Kraker ME; Stolk WA; van Oortmarssen GJ; Habbema JD
Trop Med Int Health; 2006 May; 11(5):718-28. PubMed ID: 16640625
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and effectiveness of basic lymphedema management in Leogane, Haiti, an area endemic for bancroftian filariasis.
Addiss DG; Louis-Charles J; Roberts J; Leconte F; Wendt JM; Milord MD; Lammie PJ; Dreyer G
PLoS Negl Trop Dis; 2010 Apr; 4(4):e668. PubMed ID: 20422031
[TBL] [Abstract][Full Text] [Related]
6. Multiplex bead assay for serum samples from children in Haiti enrolled in a drug study for the treatment of lymphatic filariasis.
Moss DM; Priest JW; Boyd A; Weinkopff T; Kucerova Z; Beach MJ; Lammie PJ
Am J Trop Med Hyg; 2011 Aug; 85(2):229-37. PubMed ID: 21813840
[TBL] [Abstract][Full Text] [Related]
7. Costs of integrated mass drug administration for neglected tropical diseases in Haiti.
Goldman AS; Brady MA; Direny A; Desir L; Oscard R; Vely JF; Linehan M; Baker M
Am J Trop Med Hyg; 2011 Nov; 85(5):826-33. PubMed ID: 22049035
[TBL] [Abstract][Full Text] [Related]
8. Toward the elimination of lymphatic filariasis by 2020: treatment update and impact assessment for the endgame.
Rebollo MP; Bockarie MJ
Expert Rev Anti Infect Ther; 2013 Jul; 11(7):723-31. PubMed ID: 23879610
[TBL] [Abstract][Full Text] [Related]
9. Community-wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs.
De Rochars MB; Direny AN; Roberts JM; Addiss DG; Radday J; Beach MJ; Streit TG; Dardith D; Lafontant JG; Lammie PJ
Am J Trop Med Hyg; 2004 Oct; 71(4):466-70. PubMed ID: 15516644
[TBL] [Abstract][Full Text] [Related]
10. Frequency and Clinical Significance of Localized Adverse Events following Mass Drug Administration for Lymphatic Filariasis in an Endemic Area in South India.
Kuttiatt VS; Somani RK; Swaminathan S; Krishnamoorthy K; Weil GJ; Purushothaman J
Am J Trop Med Hyg; 2020 Jan; 102(1):96-99. PubMed ID: 31769393
[TBL] [Abstract][Full Text] [Related]
11. Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000.
McLaughlin SI; Radday J; Michel MC; Addiss DG; Beach MJ; Lammie PJ; Lammie J; Rheingans R; Lafontant J
Am J Trop Med Hyg; 2003 May; 68(5):568-73. PubMed ID: 12812348
[TBL] [Abstract][Full Text] [Related]
12. The Leogane, Haiti demonstration project: decreased microfilaremia and program costs after three years of mass drug administration.
de Rochars MB; Kanjilal S; Direny AN; Radday J; Lafontant JG; Mathieu E; Rheingans RD; Haddix AC; Streit TG; Beach MJ; Addiss DG; Lammie PJ
Am J Trop Med Hyg; 2005 Nov; 73(5):888-94. PubMed ID: 16282299
[TBL] [Abstract][Full Text] [Related]
13. Coverage survey for assessing mass drug administration against lymphatic filariasis in Gulbarga district, Karnataka, India.
Ranganath BG
J Vector Borne Dis; 2010 Mar; 47(1):61-4. PubMed ID: 20231778
[No Abstract] [Full Text] [Related]
14. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
Jambulingam P; Kuttiatt VS; Krishnamoorthy K; Subramanian S; Srividya A; Raju HKK; Rahi M; Somani RK; Suryaprakash MK; Dwivedi GP; Weil GJ
PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009069. PubMed ID: 33591979
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters.
Wamae CN; Njenga SM; Ngugi BM; Mbui J; Njaanake HK
Acta Trop; 2011 Sep; 120 Suppl 1():S33-8. PubMed ID: 20933491
[TBL] [Abstract][Full Text] [Related]
16. Targeting of children in filariasis mass drug administration.
Rajendran R; Sunish IP; Mani TR; Munirathinam A; Satyanarayana K
Lancet; 2002 Nov; 360(9343):1430. PubMed ID: 12424026
[No Abstract] [Full Text] [Related]
17. Fifteen years of programme implementation for the elimination of Lymphatic Filariasis in Ghana: Impact of MDA on immunoparasitological indicators.
Biritwum NK; de Souza DK; Marfo B; Odoom S; Alomatu B; Asiedu O; Yeboah A; Hervie TE; Mensah EO; Yikpotey P; Koroma JB; Molyneux D; Bockarie MJ; Gyapong JO
PLoS Negl Trop Dis; 2017 Mar; 11(3):e0005280. PubMed ID: 28333930
[No Abstract] [Full Text] [Related]
18. Mass treatment to eliminate filariasis in Papua New Guinea.
Bockarie MJ; Tisch DJ; Kastens W; Alexander ND; Dimber Z; Bockarie F; Ibam E; Alpers MP; Kazura JW
N Engl J Med; 2002 Dec; 347(23):1841-8. PubMed ID: 12466508
[TBL] [Abstract][Full Text] [Related]
19. Changes in Antibody Levels during and following an Episode of Acute Adenolymphangitis (ADL) among Lymphedema Patients in Léogâne, Haiti.
Mues KE; Lammie PJ; Klein M; Kleinbaum DG; Addiss D; Fox LM
PLoS One; 2015; 10(10):e0141047. PubMed ID: 26492462
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of mass drug administration.
Rao RU; Nagodavithana KC; Samarasekera SD; Wijegunawardana AD; Premakumara WD; Perera SN; Settinayake S; Miller JP; Weil GJ
PLoS Negl Trop Dis; 2014; 8(11):e3281. PubMed ID: 25393404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
